PL3080103T3 - Związki biarylu użyteczne do leczenia ludzkich chorób w onkologii, neurologii i immunologii - Google Patents

Związki biarylu użyteczne do leczenia ludzkich chorób w onkologii, neurologii i immunologii

Info

Publication number
PL3080103T3
PL3080103T3 PL14825001T PL14825001T PL3080103T3 PL 3080103 T3 PL3080103 T3 PL 3080103T3 PL 14825001 T PL14825001 T PL 14825001T PL 14825001 T PL14825001 T PL 14825001T PL 3080103 T3 PL3080103 T3 PL 3080103T3
Authority
PL
Poland
Prior art keywords
neurology
oncology
immunology
treatment
compounds useful
Prior art date
Application number
PL14825001T
Other languages
English (en)
Inventor
Brian T. Hopkins
Bin Ma
Timothy Raymond CHAN
Lihong Sun
Lei Zhang
Gnanasambandam Kumaravel
Joseph P. Lyssikatos
Kevin Koch
Hua Miao
Original Assignee
Biogen Ma Inc.
Sunesis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc., Sunesis Pharmaceuticals, Inc. filed Critical Biogen Ma Inc.
Publication of PL3080103T3 publication Critical patent/PL3080103T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL14825001T 2013-12-11 2014-12-11 Związki biarylu użyteczne do leczenia ludzkich chorób w onkologii, neurologii i immunologii PL3080103T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914886P 2013-12-11 2013-12-11
PCT/US2014/069853 WO2015089337A1 (en) 2013-12-11 2014-12-11 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP14825001.2A EP3080103B9 (en) 2013-12-11 2014-12-11 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Publications (1)

Publication Number Publication Date
PL3080103T3 true PL3080103T3 (pl) 2018-10-31

Family

ID=52302344

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14825001T PL3080103T3 (pl) 2013-12-11 2014-12-11 Związki biarylu użyteczne do leczenia ludzkich chorób w onkologii, neurologii i immunologii

Country Status (32)

Country Link
US (4) US9809577B2 (pl)
EP (3) EP3872075A1 (pl)
JP (4) JP6431914B2 (pl)
KR (1) KR102413253B1 (pl)
CN (3) CN108947913A (pl)
AR (2) AR098721A1 (pl)
AU (2) AU2014362231B2 (pl)
BR (1) BR112016012860A2 (pl)
CA (1) CA2932608C (pl)
CL (2) CL2016001435A1 (pl)
CY (1) CY1120517T1 (pl)
DK (1) DK3080103T3 (pl)
EA (2) EA030538B1 (pl)
ES (1) ES2678021T3 (pl)
HR (1) HRP20181109T1 (pl)
HU (1) HUE040346T2 (pl)
IL (2) IL246031B (pl)
LT (1) LT3080103T (pl)
MX (2) MX388978B (pl)
MY (1) MY179781A (pl)
NZ (1) NZ721217A (pl)
PH (1) PH12016501107B1 (pl)
PL (1) PL3080103T3 (pl)
PT (1) PT3080103T (pl)
RS (1) RS57662B1 (pl)
SA (1) SA518391170B1 (pl)
SG (2) SG10201908558WA (pl)
SI (1) SI3080103T1 (pl)
SM (1) SMT201800373T1 (pl)
TW (3) TWI675833B (pl)
WO (1) WO2015089337A1 (pl)
ZA (1) ZA201706244B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
JP2018521029A (ja) * 2015-06-10 2018-08-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ブルトン型チロシンキナーゼのビアリール阻害剤のアジピン酸塩形態及び組成物
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2017171631A1 (en) * 2016-03-31 2017-10-05 Lion Tcr Pte. Ltd. Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)
WO2018001251A1 (zh) * 2016-06-27 2018-01-04 杭州雷索药业有限公司 苯并呋喃吡唑胺类蛋白激酶抑制剂
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
SI3609886T1 (sl) 2017-04-14 2024-05-31 Biogen Ma Inc. Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo
US11466012B2 (en) 2018-01-10 2022-10-11 Allinky Biopharma Tetrahydroisoquinoline compounds
CN117964573B (zh) 2018-01-19 2026-04-14 赛特凯恩蒂克公司 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EP3793994B1 (en) 2018-05-14 2023-08-23 Biogen MA Inc. Inhibiting agents for bruton's tyrosine kinase
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020005888A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
MA53914A (fr) * 2018-10-15 2021-08-25 Biogen Ma Inc Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
EP3969124A1 (en) * 2019-05-15 2022-03-23 Biogen MA Inc. Inhibiting agents for bruton's tyrosine kinase
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
JP7646671B2 (ja) * 2019-12-23 2025-03-17 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
EP4192587A1 (en) 2020-08-07 2023-06-14 Biogen MA Inc. Btk inhibitors
CN116917279A (zh) * 2020-08-07 2023-10-20 渤健马萨诸塞州股份有限公司 Btk抑制剂
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
BR112023025459A2 (pt) 2021-06-04 2024-02-27 Janssen Pharmaceutica Nv Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos
KR20240025529A (ko) * 2021-06-21 2024-02-27 베이진 스위찰랜드 게엠베하 (r)-글루타르이미드 crbn 리간드 및 사용 방법
MX2024008060A (es) * 2021-12-30 2024-07-10 Beigene Switzerland Gmbh Degradacion de la tirosina quinasa de bruton (btk) mediante conjugacion de inhibidores de la btk con ligando de ligasa e3 y metodos de uso.
CN116891437B (zh) * 2022-04-06 2025-10-28 长春金赛药业有限责任公司 氨基酸衍生物、药物组合物及其制备方法和应用
JP2026501703A (ja) 2023-01-04 2026-01-16 エービー サイエンス チューブリン重合阻害剤
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
WO2026012424A1 (zh) * 2024-07-10 2026-01-15 江苏恒瑞医药股份有限公司 一种杂芳基类化合物、其制备方法及其在医药上的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
NZ524100A (en) * 2000-08-08 2005-01-28 Ortho Mcneil Pharm Inc 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1713775A4 (en) * 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
ZA200804083B (en) * 2005-11-01 2009-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US8003695B2 (en) * 2006-11-01 2011-08-23 Chroma Therapeutics Ltd. IKK-beta serine-threonine protein kinase inhibitors
JP2010522241A (ja) * 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
US20120101113A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
DK2209786T3 (da) * 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
US8697685B2 (en) * 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012133310A1 (ja) 2011-03-31 2012-10-04 美津濃株式会社 アイアンゴルフクラブヘッドおよびアイアンゴルフクラブ
BR112013026202A2 (pt) 2011-04-12 2017-07-25 Myrexis Inc composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
CN107001362A (zh) * 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
SI3609886T1 (sl) 2017-04-14 2024-05-31 Biogen Ma Inc. Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo

Also Published As

Publication number Publication date
CA2932608C (en) 2023-02-14
MX2016007611A (es) 2016-09-09
DK3080103T3 (en) 2018-07-30
AU2014362231B2 (en) 2019-04-04
US20180093973A1 (en) 2018-04-05
CL2016001435A1 (es) 2017-06-09
AU2014362231A1 (en) 2016-07-07
JP7076022B2 (ja) 2022-05-26
KR102413253B1 (ko) 2022-06-27
CN108947913A (zh) 2018-12-07
CN106459002A (zh) 2017-02-22
CN106459002B (zh) 2018-08-21
EA037942B1 (ru) 2021-06-10
EA201691114A1 (ru) 2016-11-30
IL269569B (en) 2021-03-25
US11572356B2 (en) 2023-02-07
JP2018035201A (ja) 2018-03-08
US10081619B2 (en) 2018-09-25
CA2932608A1 (en) 2015-06-18
US10759783B2 (en) 2020-09-01
TW201536765A (zh) 2015-10-01
AU2019201997A1 (en) 2019-04-18
MX2019014228A (es) 2020-01-23
KR20160106072A (ko) 2016-09-09
AU2019201997C1 (en) 2021-03-18
MX370103B (es) 2019-12-02
JP6431914B2 (ja) 2018-11-28
PT3080103T (pt) 2018-07-23
JP2021091733A (ja) 2021-06-17
JP2016539996A (ja) 2016-12-22
TWI675833B (zh) 2019-11-01
PH12016501107B1 (en) 2021-07-21
CN109096274A (zh) 2018-12-28
IL246031B (en) 2019-10-31
AR098721A1 (es) 2016-06-08
US20190218204A1 (en) 2019-07-18
AR110381A2 (es) 2019-03-20
CY1120517T1 (el) 2019-07-10
EP3080103B1 (en) 2018-04-18
SA518391170B1 (ar) 2022-08-25
BR112016012860A2 (pt) 2017-08-08
US20220332705A1 (en) 2022-10-20
CL2017001459A1 (es) 2018-03-23
SMT201800373T1 (it) 2018-09-13
SG11201604595VA (en) 2016-07-28
TWI744672B (zh) 2021-11-01
EP3872075A1 (en) 2021-09-01
AU2019201997B2 (en) 2020-09-17
EA030538B1 (ru) 2018-08-31
ZA201706244B (en) 2019-04-24
HRP20181109T1 (hr) 2018-11-02
EP3080103A1 (en) 2016-10-19
EP3357921A3 (en) 2018-09-12
JP6526167B2 (ja) 2019-06-05
PH12016501107A1 (en) 2016-07-11
US20160311802A1 (en) 2016-10-27
US9809577B2 (en) 2017-11-07
EA201792348A1 (ru) 2018-09-28
MX388978B (es) 2025-03-20
IL269569A (en) 2019-11-28
ES2678021T3 (es) 2018-08-08
SI3080103T1 (sl) 2018-11-30
EP3357921A2 (en) 2018-08-08
CN109096274B (zh) 2022-07-01
TWI608002B (zh) 2017-12-11
SG10201908558WA (en) 2019-10-30
HUE040346T2 (hu) 2019-03-28
RS57662B1 (sr) 2018-11-30
EP3080103B9 (en) 2018-09-19
TW201811772A (zh) 2018-04-01
NZ721217A (en) 2021-12-24
IL246031A0 (en) 2016-08-02
WO2015089337A1 (en) 2015-06-18
MY179781A (en) 2020-11-13
LT3080103T (lt) 2018-08-10
TW202017931A (zh) 2020-05-16
JP2019163280A (ja) 2019-09-26

Similar Documents

Publication Publication Date Title
IL269569B (en) Biaryl compounds used in the treatment of human diseases in oncology, neurology and immunology
GB201320729D0 (en) Therapeutic compounds and their use
HUE039560T2 (hu) Mikro méretû zárófedés és kapcsolódó eljárások bõr kezelésére
EP2967744A4 (en) SKIN TREATMENT DEVICE
GB201403093D0 (en) Therapeutic compounds and their use
EP2994078A4 (en) COMPRESSIVE PATIENT-HEATING DEVICE
EP2952149A4 (en) THERAPEUTIC TREATMENT DEVICE
SG11201708624YA (en) Therapeutic antibodies and uses thereof
GB201311361D0 (en) Compounds and their therapeutic use
ZA201802256B (en) Compounds and therapeutic uses thereof
PT3071247T (pt) Dispositivo para a construção de pele
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
PT3016977T (pt) Anticorpos humanos anti-il-32
GB201308736D0 (en) Compounds and their therapeutic use
GB201304038D0 (en) Treated cells and therapeutic uses
GB201316521D0 (en) Therapeutic apparatus
IL257737B (en) Medical compounds based on methanopyrrolo-pyridine-carboxylate and their synthesis
GB201410954D0 (en) Skin treatment devices and methods
GB201309498D0 (en) Novel diagnosis and therapy
IL241412A0 (en) Skin care device
IL240303A0 (en) Skin care device
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use